Format

Send to

Choose Destination
Evid Based Complement Alternat Med. 2014;2014:459165. doi: 10.1155/2014/459165. Epub 2014 Jun 25.

Pterostilbene on metabolic parameters: a randomized, double-blind, and placebo-controlled trial.

Author information

1
The University of Mississippi School of Pharmacy, 2500 North State Street, Jackson, MS 39216, USA ; The University of Mississippi Medical Center, 2500 North State Street, Jackson, MS 39216, USA ; Department of Pharmacy Practice, University of Mississippi School of Pharmacy, 2500 North State Street, Jackson, MS 39216, USA ; Department of Medicine, University of Mississippi Medical Center, 2500 North State Street, Jackson, MS 39216, USA.
2
The University of Mississippi School of Pharmacy, 2500 North State Street, Jackson, MS 39216, USA ; Department of Pharmacy Practice, University of Mississippi School of Pharmacy, 2500 North State Street, Jackson, MS 39216, USA ; St. Dominic-Jackson Memorial Hospital, 969 Lakeland Drive, Jackson, MS 39216, USA.
3
The University of Mississippi Medical Center, 2500 North State Street, Jackson, MS 39216, USA ; Center of Biostatistics, University of Mississippi Medical Center, 2500 North State Street, Jackson, MS 39216, USA.
4
Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA.
5
The University of Mississippi School of Pharmacy, 2500 North State Street, Jackson, MS 39216, USA ; Department of Pharmacy Practice, University of Mississippi School of Pharmacy, 2500 North State Street, Jackson, MS 39216, USA.
6
The University of Mississippi Medical Center, 2500 North State Street, Jackson, MS 39216, USA ; Department of Medicine, University of Mississippi Medical Center, 2500 North State Street, Jackson, MS 39216, USA.
7
The University of Mississippi Medical Center, 2500 North State Street, Jackson, MS 39216, USA ; Department of Medicine, University of Mississippi Medical Center, 2500 North State Street, Jackson, MS 39216, USA ; Center of Biostatistics, University of Mississippi Medical Center, 2500 North State Street, Jackson, MS 39216, USA.

Abstract

INTRODUCTION:

The purpose of this trial was to evaluate the effect of pterostilbene on metabolic parameters.

METHODS:

A prospective, randomized, double-blind, and placebo-controlled study that enrolled 80 patients with a total cholesterol ≥200 mg/dL and/or LDL ≥ 100 mg/dL. Subjects were divided into four groups: (1) pterostilbene 125 mg twice daily; (2) pterostilbene 50 mg twice daily; (3) pterostilbene 50 mg + grape extract (GE) 100 mg twice daily; (4) matching placebo twice daily for 6-8 weeks. Endpoints included lipids, blood pressure, and weight. Linear mixed models were used to examine and compare changes in parameters over time. Models were adjusted for age, gender, and race.

RESULTS:

LDL increased with pterostilbene monotherapy (17.1 mg/dL; P = 0.001) which was not seen with GE combination (P = 0.47). Presence of a baseline cholesterol medication appeared to attenuate LDL effects. Both systolic (-7.8 mmHg; P < 0.01) and diastolic blood pressure (-7.3 mmHg; P < 0.001) were reduced with high dose pterostilbene. Patients not on cholesterol medication (n = 51) exhibited minor weight loss with pterostilbene (-0.62 kg/m(2); P = 0.012).

CONCLUSION:

Pterostilbene increases LDL and reduces blood pressure in adults. This trial is registered with Clinicaltrials.gov NCT01267227.

Supplemental Content

Full text links

Icon for Hindawi Limited Icon for PubMed Central
Loading ...
Support Center